- Home
- CNEY vs PHIO Comparison
CNEY vs PHIO Comparison
Compare CNEY & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- PHIO
- Stock Information
- Founded
- CNEY 2018
- PHIO 2011
- Country
- CNEY China
- PHIO United States
- Employees
- CNEY N/A
- PHIO N/A
- Industry
- CNEY Major Chemicals
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- PHIO Health Care
- Exchange
- CNEY Nasdaq
- PHIO Nasdaq
- Market Cap
- CNEY 12.9M
- PHIO 13.5M
- IPO Year
- CNEY 2021
- PHIO N/A
- Fundamental
- Price
- CNEY $2.09
- PHIO $2.20
- Analyst Decision
- CNEY
- PHIO Strong Buy
- Analyst Count
- CNEY 0
- PHIO 3
- Target Price
- CNEY N/A
- PHIO $10.67
- AVG Volume (30 Days)
- CNEY 42.1K
- PHIO 136.6K
- Earning Date
- CNEY 01-01-0001
- PHIO 11-13-2025
- Dividend Yield
- CNEY N/A
- PHIO N/A
- EPS Growth
- CNEY N/A
- PHIO N/A
- EPS
- CNEY N/A
- PHIO N/A
- Revenue
- CNEY $36,049,275.00
- PHIO N/A
- Revenue This Year
- CNEY N/A
- PHIO N/A
- Revenue Next Year
- CNEY N/A
- PHIO N/A
- P/E Ratio
- CNEY N/A
- PHIO N/A
- Revenue Growth
- CNEY N/A
- PHIO N/A
- 52 Week Low
- CNEY $1.56
- PHIO $0.97
- 52 Week High
- CNEY $21.61
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CNEY 39.50
- PHIO 45.33
- Support Level
- CNEY $2.08
- PHIO $2.28
- Resistance Level
- CNEY $2.36
- PHIO $2.45
- Average True Range (ATR)
- CNEY 0.17
- PHIO 0.13
- MACD
- CNEY -0.03
- PHIO -0.01
- Stochastic Oscillator
- CNEY 0.57
- PHIO 11.63
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.